Elevation Oncology Inc (ELEV)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
BIOLOGICAL PRODUCTS, (NO DISGNOSTIC SUBSTANCES)
CEO:
Shawn M. Leland
Employees:
40
888 SEVENTH AVE, 12TH FLOOR, NEW YORK, NY 10106
212-651-6380

Elevation Oncology focuses on developing therapeutics for the treatment of cancer in genomically defined patient populations in the United States. The company's lead program is the seribantumab, an anti-HER3 monoclonal antibody that is in Phase II CRESTONE trial.

Data derived from most recent annual or quarterly report
Market Cap 23.483 Million Shares Outstanding23.25 Million Avg 30-day Volume 51.481 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-3.8
Price to Revenue0.0 Debt to Equity0.0 EBITDA-59.365 Million
Price to Book Value0.3111 Operating Margin0.0 Enterprise Value-89.98 Million
Current Ratio6.478 EPS Growth0 Quick Ratio6.418
1 Yr BETA 0.7824 52-week High/Low 7.5 / 0.86 Profit Margin0.0
Operating Cash Flow Growth-87.6555 Altman Z-Score-0.5911 Free Cash Flow to Firm 0

Are you looking for this stock instead?

View SEC Filings from ELEV instead.

View recent insider trading info

Funds Holding ELEV (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding ELEV

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Events (8k)

  • 8-K: filed on 2022-11-03:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-08-04:
    Item 2.02: Results of Operations and Financial Condition
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2022-07-28:
    Item 1.01: Entry into a Material Definitive Agreement
    Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
    Item 3.02: Unregistered Sales of Equity Securities
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    AISLING CAPITAL IV, LP

    AISLING CAPITAL PARTNERS IV LLC

    AISLING CAPITAL PARTNERS IV, LP

    ELMS STEVE

    SCHIFF ANDREW N

    • Director
    • 10% Owner
    15,619 2022-06-17 1

    CLACKSON TIMOTHY P

    • Director
    62,949 2022-06-17 1

    CARRUTHERS R MICHAEL

    • Director
    15,619 2022-06-17 1

    HU LORI

    • Director
    15,619 2022-06-17 1

    WALSH COLIN

    • Director
    15,619 2022-06-17 1

    VENBIO GLOBAL STRATEGIC FUND III, L.P.

    VENBIO GLOBAL STRATEGIC GP III, L.P.

    GOODMAN COREY S

    ADELMAN ROBERT J

    ROYSTON AARON

    1,905,430 2022-05-25 1

    DORNAN DAVID CHIEF SCIENTIFIC OFFICER

    • Officer
    230,000 2022-03-14 2

    FERRA JOSEPH J JR CHIEF FINANCIAL OFFICER

    • Officer
    60,000 2022-02-14 1

    LELAND SHAWN PRESIDENT, CEO

    • Officer
    • Director
    186,500 2022-02-14 1

    JANSEN VALERIE MALYVANH CHIEF MEDICAL OFFICER

    • Officer
    60,000 2022-02-14 1

    CORMORANT ASSET MANAGEMENT, LP

    CHEN BIHUA

    CORMORANT GLOBAL HEALTHCARE MASTER FUND, LP

    CORMORANT PRIVATE HEALTHCARE FUND III LP

    • 10% Owner
    • FORMER 10% OWNER
    No longer subject to file 2021-06-29 0

    QIMING U.S. HEALTHCARE FUND II, L.P.

    QIMING U.S. HEALTHCARE GP II, LLC

    • 10% Owner
    2,370,142 2021-06-29 0

    VERTEX GLOBAL HC FUND II PTE. LTD.

    • 10% Owner
    2,307,642 2021-06-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed
    Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 22:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 21:45:04 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 21:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 20:45:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 20:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 19:45:04 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 19:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 18:45:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 18:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 17:45:04 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 17:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 16:45:04 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 16:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 15:45:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 15:15:03 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 14:45:04 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 14:15:04 UTC -5.7554 9.5754 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 13:45:03 UTC -5.7808 9.6008 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 13:15:03 UTC -5.7808 9.6008 90000
    ELEVATION ONCOLOGY INC ELEV 2022-11-25 12:45:03 UTC -5.7808 9.6008 90000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    Elevate your investments